Androgen receptor (AR) signaling regulates the development and homeostasis of male reproductive organs, including the prostate. Deregulation of AR and AR coregulators, expression, or activity is involved in the initiation of prostate cancer and contributes to the transition of the disease to hormone-refractory stage. The ubiquitous Arrestin proteins are now recognized as bona fide adapters and signal transducers with target effectors found in both the cytosol and nucleus. Here, we provide evidence that Arrestin2 forms a complex with AR and acts as an AR corepressor in androgen-dependent prostate cancer cells. Accordingly, the forced overexpression of Arrestin2 diminishes, and knockdown of Arrestin2 expression with RNAi increases the androgen-induced prostate-specific antigen (PSA) gene expression. Arrestin2 serves as an adapter, bringing into close proximity the Mdm2 E3 ligase and AR, thereby promoting AR ubiquitylation and degradation. Human prostate tissues evidence an inverse relationship between the expression of Arrestin2 and AR activity: glands that express high levels of Arrestin2 exhibit low expression of PSA, and those glands that express low levels of Arrestin2 evidence elevated PSA levels. We conclude that Arrestin2 acts as a corepressor of AR by serving as a scaffold for Mdm2 leading to the AR ubiquitylation and degradation.beta-arrestin ͉ ubiquitin ͉ Mdm2 ͉ testosterone ͉ androgen deprivation therapy P rostate cancer accounts for approximately one-third of all male cancer cases in the United States, and 186,320 cases were diagnosed in 2008 (1). The cancer often presents as an androgendependent (AD), hormone-sensitive disease that can be successfully managed with targeted therapies that aim to inhibit function of the androgen receptor (AR). Although these therapies are initially effective, a significant portion of the cancer patients develop advanced androgen-independent (AI), hormone-refractory disease (2). Not surprising then, effective management of prostate cancer remains elusive and an estimated 28,660 American lives were claimed by the disease in 2008 alone (1). The deregulation of expression and activity of AR, and AR-interacting partners, is thought to be involved in the progression of the prostate cancer to advanced disease (3, 4).The AR is a member of the nuclear hormone receptor superfamily of ligand-controlled transcription factors, and it regulates expression of multiple genes that are involved in the normal development and malignant transformation of the prostate (4-6). Recent evidence suggests that the AR also participates in the transition of the prostate cancer to AI disease (7). Indeed, approximately one-third of AI prostate carcinomas show amplification and overexpression of the wild-type AR, suggesting it adjusts to capture the low levels of circulating androgen (8, 9). In another one-third of AI cancer, the AR is mutated allowing it to become activated by other steroids or even anti-androgens (2, 10). In the remaining one-third of AI prostate cancers, no discernable AR m...